Urelumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD137 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
| Chemical and physical data | |
| Formula | C6502H9972N1712O2030S44 |
| Molar mass | 145.8 kg/mol g·mol−1 |
  (what is this?) (verify) | |
Urelumab (BMS-663513 or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer and solid tumors.[1]
Urelumab targets the extracellular domain of CD137.[2] It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells.[3]
The first phase I trial began in 2006 and final results were published in 2015.[4]
Current clinical trials combine urelumab with chemotherapy (NCT00351325), chemoradiation (NCT00461110), ipilimumab (NCT00803374), rituximab (NCT01775631, NCT02420938), cetuximab (NCT02110082), and elotuzumab (NCT02252263), nivolumab (NCT02253992) for metastatic solid tumors, NSCLC, melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, and multiple myeloma. A biomarker study using CyTOF is also underway.[5]
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab" (PDF). American Medical Association.
- ^ http://web.stanford.edu/~sdutt/PDF/2015_SD_yonezawa.pdf
- ^ "Urelumab". National Cancer Institute.
- ^ https://clinicaltrials.gov/ct2/show/NCT00309023?term=NCT00309023&rank=1
- ^ http://web.stanford.edu/~sdutt/PDF/2015_SD_yonezawa.pdf
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |